ADC Therapeutics SA

09/29/2021 | Press release | Distributed by Public on 09/29/2021 05:23

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma (Form 6-K)